☰

Niharika B. Mettu, Ph.D. - Publications

Affiliations: 
2007 Duke University, Durham, NC 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Journal For Immunotherapy of Cancer. 8. PMID 32114502 DOI: 10.1136/Jitc-2020-000587  0.333
2020 Gutierrez M, Subbiah V, Nemunaitis JJ, Mettu NB, Papadopoulos KP, Barve MA, Féliz L, Lihou CF, Tian C, Ji T, Silverman IM, Chugh R, Saleh MN. Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study. Journal of Clinical Oncology. 38: 3606-3606. DOI: 10.1200/Jco.2020.38.15_Suppl.3606  0.307
2019 Subbiah V, Barve M, Iannotti NO, Gutierrez M, Smith DC, Roychowdhury S, Papadopoulos KP, Mettu N, Edenfield WJ, Morgensztern D, Féliz L, Lihou C, Zhen H, Saleh M. Abstract A078: FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A078  0.323
2018 Mettu NB, Niedzwiecki D, Boland PM, Fakih M, Arrowood C, Bolch E, Hurwitz H, Grothey A. BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer. Journal of Clinical Oncology. 36: TPS873-TPS873. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps873  0.324
2007 Mettu NB, Stanley TB, Dwyer MA, Jansen MS, Allen JE, Hall JM, McDonnell DP. The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Molecular Endocrinology (Baltimore, Md.). 21: 2361-77. PMID 17595321 DOI: 10.1210/Me.2007-0201  0.357
Show low-probability matches.